Jonathan Dickinson

“Good morning to those joining from the U.S. and good afternoon to our European participants. Turning to slide five. Since our first half update, we have continued to advance our focus portfolio while strengthening our financial position.”

“Good morning to those joining from the U.S. and good afternoon to our European participants. Turning to slide five, the first half of 2026, together with development since the end of the period, has been marked by important progress across our focus portfolio.”

“Yeah, so I think our strategy doesn't really change, versus where we were, I guess, roughly a year ago. So about a year ago, we changed our strategy and we really focused on our three core assets.”

“Good morning to those joining from the US and good afternoon to our European participants. Turning to slide five, we continue to execute against our strategy, which is focused on our three priority assets with discipline, and we're pleased with the strong progress we are seeing today.”

“Turning to slide five, Innate Pharma is a focused oncology company with a clear ambition to deliver high value differentiated therapies for patients with significant unmet medical need.”